Skip to content
Open access

PARP1 Deficiency Attenuates Cisplatin Nephrotoxicity and Renal COX-2/PGE2 Response

Oct 2026 · Cells · Vol 15, pp. 1810 · 0 citations · 81 references
Medicine

TL;DR

It is demonstrated that PARP1 deficiency attenuates cisplatin-induced renal dysfunction, tubular injury, and inflammatory responses and the suppression of NF-κB activation and the COX-2/PGE2 response as features of this protective phenotype support a potential PARP1–NF-κB–COX-2/PGE2 signaling axis in cisplatin nephrotoxicity.

Abstract

Highlights What are the main findings? PARP1 deficiency attenuates cisplatin-induced renal dysfunction, tubular injury, and inflammatory gene expression. Loss of PARP1 markedly suppresses the cisplatin-induced renal Ptgs2/COX-2/PGE2 response. What are the implications of the main findings? The renal COX-2/PGE2 response represents a potential downstream molecular response associated with PARP1 during cisplatin nephrotoxicity. The findings support a potential PARP1–NF-κB–COX-2/PGE2 signaling axis associated with cisplatin-induced kidney inflammation. Abstract Cisplatin is a widely used chemotherapeutic agent whose clinical utility is limited by nephrotoxicity, characterized by tubular injury and renal inflammation. Poly(ADP-ribose) polymerase 1 (PARP1) contributes to cisplatin-induced kidney injury and inflammatory signaling, but the downstream inflammatory pathways involved remain incompletely defined. Here, we investigated whether PARP1 modulates the renal cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) response during cisplatin-induced acute kidney injury (AKI). Female wild-type and Parp1-knockout (KO) mice on a C57BL/6 background received a single intraperitoneal injection of cisplatin (20 mg/kg) and were evaluated at days 1 and 4, while male mice were evaluated at day 4 for renal function. Renal function, tubular injury, inflammatory gene expression, NF-κB activation, Ptgs2 mRNA and COX-2 protein expression, and kidney PGE2 levels were assessed. Cisplatin markedly increased plasma creatinine and blood urea nitrogen levels and induced tubular injury in both the renal cortex and outer stripe of the outer medulla, whereas these changes were significantly attenuated in Parp1 KO mice at day 4. At day 4, cisplatin-induced renal expression of Il1b, Il6, Ccl5, Cxcl1, and Cxcl2 was also substantially reduced by Parp1 deficiency. Cisplatin increased renal NF-κB p65 activation, as assessed by the p-p65/t-p65 ratio, in wild-type mice, whereas this response was significantly attenuated in Parp1 KO mice. Consistently, cisplatin increased renal Ptgs2 mRNA expression, COX-2 protein abundance, and PGE2 levels in wild-type mice, whereas all three responses were significantly attenuated in Parp1 KO mice. In particular, the cisplatin-induced increase in renal PGE2 was nearly abolished in the absence of PARP1. These findings demonstrate that PARP1 deficiency attenuates cisplatin-induced renal dysfunction, tubular injury, and inflammatory responses and identify suppression of NF-κB activation and the COX-2/PGE2 response as features of this protective phenotype. The results support a potential PARP1–NF-κB–COX-2/PGE2 signaling axis in cisplatin nephrotoxicity.

Read PDF

Similar papers

Open access Sep 2026

Therapeutic Potential of Trilobatin in Cisplatin-Induced Kidney Injury: Targeting Ferroptosis and Inflammation

Cisplatin-induced acute kidney injury (CI-AKI) is a common and severe complication in cancer patients undergoing chemotherapy, which can progress to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Ferroptosis and inflammation are critical pathological mechanisms underlying CI-AKI. Trilobatin (TLB),...

Yang Xiang, Die Zhang, Qiang-Fang Dai et al. · 0 citations
Open access Sep 2026

Echinacoside Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating Bap1 to Inhibit Ferroptosis

Background/Objectives: Cisplatin-induced acute kidney injury (AKI) is a major adverse complication restricting cisplatin-based chemotherapy. Ferroptosis contributes substantially to proximal tubular epithelial injury during AKI. This work aimed to explore the renoprotective effect of echinacoside (ECH) and its underlyi...

Li-Jia Chen, Ming-Jie Zhang, M. Chi et al. · 0 citations
Review Aug 2026

Deciphering Gentamicin-Induced Nephrotoxicity and Hepatotoxicity: Pathophysiological Insights and Emerging Protective Approaches.

Evidence is consolidated on GEN's pharmacological profile, pathophysiological mechanisms of both organ toxicities, predisposing risk factors, and protective agents demonstrating preclinical efficacy, as well as a proposed multi-target hepatorenoprotective framework.

Ehab E. Sharata, Reham H. Mohyeldin, Mahmoud Abdelnaser et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.